AbbVie Biotech Ventures

What is AbbVie Biotech Ventures?

AbbVie Biotech Ventures, Inc. (ABVI), stationed in North Chicago, Illinois, operates as a corporate venture capital entity and a subsidiary of AbbVie. Their mission revolves around making strategic venture capital investments in emerging biotech and pharmaceutical companies. Unlike traditional VCs, ABVI values an investment's success not just through financial returns, but notably by its potential to significantly bolster AbbVie's strategic growth.

Companies that pique ABVI's interest typically have programs that span the range from pre-clinical stages (18 months prior to first-in-human trials) to early proof-of-concept. Technologies that are central to AbbVie’s core areas like neuroscience, immunology, virology, and oncology are primarily targeted for investments.

ABVI also remains open to investing in emerging or opportunistic areas that could augment AbbVie’s current product offers or broaden the company's future market scope. When it comes to investment profiles, ABVI is willing to allocate funds ranging from a few hundred thousand dollars to several million dollars based on the development stage and nature of the opportunity.

Despite this flexibility in investment size, with minimum investments starting around $5,900,000 and capping at $73,000,000, ABVI maintains a fixed stance on being a minority investor in its dealings. Their strategy focuses on early to merging stages of company development, ensuring they can influence growth and innovation while aligning with AbbVie's business and strategic directives.